Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
SLAMF7
Name:
SLAM family member 7
Location:
01q23.3
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT03948035 | Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone E-KRd Versus KRd in MM | View | |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | View | |
| NCT05981209 | Elotuzumab CC-92480 and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | View | |
| NCT03958656 | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | View | |
| NCT04499339 | A Phase IIIa Clinical Trial to Assess Feasibility Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | View | |
| NCT03003728 | 2015-10 Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant ASCT | View | |
| NCT03168100 | 2017-03 A Single-Arm Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 Anti-SLAMF7 Monoclonal Antibody mAb Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | View | |
| NCT04156269 | BCMA-CS1 Compound CAR cCAR T Cells for RelapsedRefractory Multiple Myeloma | View | |
| NCT05170789 | Elotuzumab Selinexor and Dexamethasone for Relapsed Refractory Multiple Myeloma | View | |
| NCT04864522 | Phase III Study of SLAMF7 FPBMCCS-1 FPBMC in RelapsedRefractory Multiple Myeloma | View | |
| NCT03000634 | 2015-09 a Phase II Randomized Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | View |